CAR-T Cell Therapy in India
CAR-T cell therapy is a personalised cellular immunotherapy in which a patient's T cells are collected, genetically modified to recognise a target on cancer cells, expanded and infused back into the patient. It is used for selected blood cancers.
At a glance
- Category
- Cellular Therapy
- Procedure
- 5 key stages
Indicative only. Your specialist will confirm what applies to you.
What Is CAR-T Cell Therapy?
CAR-T therapy re-engineers a patient's T cells to express a chimeric antigen receptor that recognises a specific target on cancer cells. The pathway includes cell collection, manufacturing, preparative chemotherapy, CAR-T infusion and close monitoring for immune-related complications.
When Is CAR-T Cell Therapy Considered?
CAR-T is generally considered for specific haematological cancers and disease settings defined by the CAR-T product, prior treatments, target expression and patient fitness. It is not a routine treatment for most solid tumours.
Eligible blood cancer and treatment setting
CAR-T is used for selected leukaemias, lymphomas and multiple myeloma depending on the product and prior treatment.
Target and disease criteria are met
The cancer must match the target and eligibility requirements for the planned CAR-T therapy.
Patient can safely undergo cellular therapy
Organ function, infection status and overall clinical condition are assessed before treatment.
Conditions Treated
Non-Hodgkin Lymphoma
CAR-T may be used for selected relapsed or refractory B-cell lymphomas.
About this conditionMultiple Myeloma
CAR-T is an option for selected relapsed or refractory myeloma.
About this conditionLeukaemia
CAR-T may be appropriate for selected relapsed or refractory blood cancers.
About this condition
How CAR-T Cell Therapy Works
- 1
Eligibility review
The cellular-therapy team confirms diagnosis, prior treatments and suitability.
- 2
T-cell collection
T cells are collected from the blood, usually by leukapheresis.
- 3
Laboratory engineering and expansion
The cells are genetically modified to express the CAR and expanded.
- 4
Lymphodepleting chemotherapy
Preparative chemotherapy is usually given shortly before CAR-T infusion.
- 5
CAR-T infusion and monitoring
The cells are infused and the patient is monitored closely for immune and neurological toxicities.
Preparation Before Treatment
Preparation includes confirmation of diagnosis and eligibility, organ-function assessment, infection screening, disease-control planning during manufacturing and arrangements for close monitoring after infusion.
Collect complete haematology records
Pathology, molecular results, prior regimens and response history are essential.
Assess infections and organ function
Cardiac, kidney, liver and infection status are reviewed.
Plan the manufacturing interval
The team considers whether bridging therapy is needed while CAR-T cells are being prepared.
Technique & Technology
Different CAR-T products target different antigens, such as CD19 or BCMA, and are approved or used for different blood-cancer settings.
- 01
Target-specific CAR design
CAR-T products are engineered to recognise defined cancer-cell targets such as CD19 or BCMA.
- 02
Specialised toxicity monitoring
Structured monitoring and rapid treatment of cytokine release syndrome and neurological toxicity are central to safe delivery.
Recovery & What to Expect After Treatment
Patients require close monitoring after infusion because important toxicities can develop quickly. Follow-up continues after discharge because infection risk, low blood counts and delayed effects can persist.
Risks & Important Considerations
Major risks include cytokine release syndrome, neurological toxicity, infections, prolonged low blood counts and other immune effects. Treatment should occur in a centre experienced in recognising and managing these complications.
Potential benefits
Can produce deep responses in selected difficult-to-treat blood cancers
CAR-T can be effective in some relapsed or refractory disease settings.
Important to know
Eligibility is highly specific
The cancer type, prior treatment and product indication determine whether CAR-T is an option.
Possible risks
Cytokine release syndrome
An intense immune response can cause fever, low blood pressure and organ dysfunction and may require urgent treatment.
Neurological toxicity
Confusion, language problems, seizures or other neurological effects can occur.
Limitations
It is a complex multi-step therapy
Manufacturing time, specialised hospital resources and prolonged follow-up are required.
CAR-T Cell Therapy Cost in India
The cost of car-t cell therapy in India varies according to the exact treatment plan, clinical complexity, centre, investigations and any additional care required.
What affects the cost
- Treatment technique and complexity
- Hospital or treatment centre
- Investigations and planning
- Anaesthesia or specialised equipment where required
- Length of stay and monitoring
- Complications or additional treatment
Numeric pricing should be published only after Fabtitude validates the current treatment estimate for the specific procedure and clinical pathway.
Treatment Duration & Stay in India
The pathway is longer than the infusion itself because cell collection, manufacturing, bridging treatment when needed, preparative chemotherapy and post-infusion monitoring all add time.
Before treatment
Specialist review, required investigations and treatment planning are completed before the procedure or therapy begins.
Treatment and early recovery
The immediate treatment period depends on the exact technique, complexity and whether inpatient monitoring is required.
Follow-up and travel planning
Recovery, pathology or response assessment and fitness for long-distance travel should be reviewed before returning home.
Frequently Asked Questions About CAR-T Cell Therapy
Find out whether CAR-T Cell Therapy is right for you
Have your reports reviewed by a specialist before you travel. Suitability can only be confirmed after an individual assessment.